1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Nonalcoholicsteatohepatitis (NASH) - Pipeline Analysis

Nonalcoholicsteatohepatitis (NASH) - Pipeline Analysis

  • July 2015
  • -
  • IQ4I Research & Consultancy Pvt. Ltd
  • -
  • 112 pages

“Nonalcoholicsteatohepatitis(NASH)PipelineAnalysis”givescomprehensiveinsightonthevariousdrugsbeingdevelopedforthetreatmentofNASH.Thereportcoversallthedrugsbeingdevelopedinvariousphases(Discovery,Preclinical&Clinicaldevelopment).Thepipelinefocusesonnovelmedicinescoveringsmallmolecules,monoclonalantibodies,RecombinantproteinsandRNA-basedtherapeutics,butexcludesOff-label,symptomreliefdrugs,genericcombinations.ThereportalsocovershottargetsinresearchforNASHtreatmentsanddiseaseprogressionbiomarkers.
ThisreportenablesPharmaceutical/Biotechcompanies,Academicinstitutes,Individualresearchers,Investors,Medicaltechnologycompanies,Serviceprovidersandotherassociatedstakeholderstoidentifyandanalyzetheavailablelicensing/collaborativecommercialopportunitiesintheNonalcoholicsteatohepatitis(NASH)Drugmarket.ThereportalsoprovidesstrategicinsightsonmedicinesthatarelikelytohaveanimpactonfutureNASHtreatmentspace.
NASHisassociatedwithfattyliver,hepaticinflammation,hepatocyteinjuryandfibrogenesisandmayworsenintofibrosisorcirrhosis,liverfailureandrarelyintolivercancer.Currently,therearenoapproveddrugsforNASHbyU.S.FoodandDrugAdministration(FDA)andthereahighunmetclinicalneed.NASH,ifuntreatedcanprogresstoliver-destroyingcirrhosisandpotentiallycancer.MajorityoftheNASHpipelinedrugsarefromspecialisedsmalltomidpharmaceutical&biotechcompanies.AssomeofthecandidatesarenearingkeyR&Dmilestones,thereisahugecompetitionamonglargepharmaceuticalandbiotechcompaniestoacquiretheseassets.Gilead’sacquisitionofPhenexFXRprogram&Boehringer’sacquisitionofNASHclinicalassetfromPharmaxissupportsthistrend.DiagnosisofNASHstillrequireshistologicalconfirmationandthereisagreatdemandforspecificnon-invasivediagnosisfordistinguishingNASHfromotherliverdiseases.Therefore,thereisaneedtodevelopbetterdiagnosticandtherapeuticstrategiesforpatientswithNASH.
ThereisatremendousopportunityforupcomingtherapiesspecifictoNASHsuchasMAbs,RNA-basedtherapies&Recombinantproteins.ThesemodalitiesmayprovideAnti-fibrosis,Anti-inflammatoryandmetabolicbenefits.

Table Of Contents

Nonalcoholicsteatohepatitis (NASH) - Pipeline Analysis
REPORT DESCRIPTION INTRODUCTION
- Causes and Symptoms
- Diagnosis
- Unmet needs
- Current therapies
HOT TARGETS, MECHANISMS and THERAPIES
- Novel Disease mechanisms and therapies
- Leading and hot targets of NASH
- Novel targets of NASH
- NASH biomarkers - Genes involved in NASH
MARKET DATA
- Forecasting model
- Market dynamics
- Market sizing
- NASH Deals
PIPELINE ANALYSIS
- Development stage
- Leading players
- Therapeutic segmentation
- Target analysis
- Innovative approaches
Small molecules
- Pipeline
- Competitive landscape Large molecules
- Competitive landscape RNA-BASED THERAPY
- Pipeline
- Competitive landscape RECOMBINANT PROTEINS
- Pipeline
- Competitive landscape ANTIBODIES
- Pipeline
- Competitive landscape LARGE MOLECULES (UNSPECIFIED)
- Pipeline
OTHER MOLECULES
- Pipeline
NASH DRUG ANALYSIS BASED ON MECHANISM
MAJOR PLAYERS
- Company Profiles
- Overview, Pipeline and Deals

companies mentioned

BOEHRINGER INGELHEIM GMBH
CERENIS THERAPEUTICS CONNEXIOS LIFE SYSTEMS
GALECTIN THERAPEUTICS
GENFIT
GILEAD SCIENCES INC
INTERCEPT PHARMACEUTICALS
ISLET SCIENCES
NGM BIOPHARMACEUTICALS NIMBUS THERAPEUTICS VERVA PHARMACEUTICALS VIKING THERAPEUTICS

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025 Summary Myelofibrosis (MF) is a rare blood disorder, which is characterized by bone marrow fibrosis. Currently, there is ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.